The Center for Drug Evaluation (CDE) has indicated that Zhejiang Erying Pharmaceutical Co., Ltd’s acetaminophen is slated for priority review, categorized as a new pediatric drug aligning with children’s physiological needs. The drug is indicated for fever caused by cold or influenza in children, as well as mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, and neuralgia.
Drug Details
The priority review status reflects the drug’s potential to address unmet needs in pediatric care. Acetaminophen, a widely used analgesic and antipyretic, is being reviewed for its suitability in formulations tailored for children.
Significance
The CDE’s move underscores China’s focus on improving pediatric medication access. Zhejiang Erying’s product aims to provide a safe and effective option for managing common childhood ailments, with the priority review likely to expedite its market entry.-Fineline Info & Tech
